ClinicalTrials.gg
CompletedNCT02710656Updated Jan 23, 2020

Study Comparing Legflow Versus Bare Balloon Angioplasty for Treatment of Atherosclerotic Disease

An interventional study of Legflow® balloon and Standard PTA in Atherosclerosis, sponsored by Cardionovum GmbH. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-23.

Sponsored by Cardionovum GmbH · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Atherosclerosis with a site in Belgium — 5 open to participants now, 9 under way, 6 of them phase 3. Atherosclerosis · Belgium.

Enrollment
26th of 39
130 · median 328
Started
2016
with 2 others
No phase
17 of 46
1 open now
Registered
28th of 46
by date

Among the 46 studies in Atherosclerosis with a site in Belgium, this one is the 26th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 17 with no phase, and was the 28th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

5 of the 46 studies in Atherosclerosis with a site in Belgium are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Atherosclerosis with a site in Belgium, or all of them as a file.
02

Study summary

A randomized multicentric study for endovascular treatment of patients with obstructive disease in the SFA (superficial femoral artery) and in the popliteal artery.

Read the detailed description

This interventional study will collect data about the treatment of de novo lesions or restenotic lesions. Restenotic lesions that are previously DCB (drug coated balloon) treated or in-stent restenosis are excluded in this study.

The primary objective of this randomized study is to compare the efficacy of the DCB (Legflow - Cardionovum) versus POBA for the treatment of de novo lesions or restenosis in the SFA and in the popliteal artery (segment P1 -P2) by assessing the binary restenosis rate with duplex ultrasonography at 12 months.

The secondary endpoints are the assessment of the immediate procedural outcome, distribution of Rutherford, mortality, target lesion revascularization (TLR), target extremity revascularization (TER), amputation and anklebrachial index (ABI).

For each patient enrolled, data will be collected up to 12 months after the procedure.

03

Conditions studied

  • Atherosclerosis

Keywords

  • Atherosclerosis
  • SFA
  • Poplitea
  • Drug coated balloon
  • Angioplasty
  • Restenosis
  • Peripheral artery disease (PAD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must sign the form prior to the index-procedure.
  2. Patient must be older than 18 years.
  3. Patient with Rutherford 2, 3 and 4..
  4. Target lesion is an occlusion or ≥70% stenosis (visual estimate) located in SFA or popliteal artery (P1 -P2).
  5. Maximum length of the target lesion is 13 cm.
  6. Target lesion is TASC A, B or C.
  7. Target lesion is a de novo lesion or restenotic lesion (previously POBA treated, in-stent restenosis is not allowed).
  8. Inflow arteries are free from hemodynamically significant obstruction (i.e. ≥ 50% diameter stenosis). It is allowed to treat inflow lesions during the index-procedure if the result is ≤ 30% diameter stenosis (treatment with DCB or DES is not allowed). Treatment of a non-target lesion in the target vessel is allowed if the nontarget lesion is considered to be an inflow lesion.
  9. Popliteal artery P3 segment (below knee popliteal artery) is free from hemodynamically significant obstruction (i.e. ≥ 50%). Treatment of a lesion in this segment is not allowed during the index-procedure.
  10. At least 1 patent (\< 50% diameter stenosis) below-the-knee vessel (anterior tibial artery, posterior tibial artery or peroneal artery) till the ankle as confirmed by baseline angiography.

Exclusion criteria

Exclusion Criteria:

  1. Patient is already included in this study (recruitment of the contralateral leg is not allowed).
  2. Patient has a known intolerance to antiplatelet therapy or contrast agent.
  3. Patient with known sensitivity to Paclitaxel.
  4. Patient is pregnant or patient intends to become pregnant within 1 year after the index-procedure.
  5. Patient takes esomeprazole or omeprazole.
  6. Patient with serum creatinine >2.0 mg/dL or renal dialysis.
  7. Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability.
  8. Patient has a \<2 years.
  9. Patient with Rutherford 0, 1 , 5 and 6.
  10. Patient has a target lesion that is severely calcified (grade 3 and grade 4).
  11. Patient with a TASC D lesion.
  12. Patient has an acute thrombus or aneurysm in the target vessel.
  13. Patient has a target lesion that cannot be crossed with a guidewire.
  14. Target vessel has been treated previously with a DCB or a DES.
  15. Treatment of outflow lesions during the index-procedure.
  16. Patients with significant disease of all 3 infrapopliteal vessels (i.e. ≥ 50% diameter stenosis in each vessel).
  17. Any scheduled surgery within 3 months after the index-procedure that would necessitate the discontinuation of clopidogrel.
  18. Patients with previous bypass surgery involving the SFA.
  19. Patient has cirrhosis of the liver.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Drug Coated Balloon (DCB) - Legflow®

    Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.

    Device: Legflow® balloon

  • Active comparator
    Standard PTA - POBA

    Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).

    Device: Standard PTA

Interventions

  • DeviceLegflow® balloon

    Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel

    Also known as: Paclitaxel eluting balloon

  • DeviceStandard PTA

    Percutaneous angioplasty performed with a standard balloon

    Also known as: POBA

06

What researchers measure

Primary outcomes

  1. Efficacy measured by binary restenosis rate

    Binary restenosis rate determined by duplex ultrasonography at 1, 6 and 12 months afte procedure. Binary restenosis is defined as a re-obstruction ≥50% of the target lesion (peak systolic velocity ratio \> 2.4).

    Time frame: Until 12 months after procedure

Secondary outcomes

  1. Immediate procedural outcome of percutaneous balloon angioplasty

    Investigator opinion of procedural and technical success of the percutaneous angioplasty. Opinion of investigator (yes/no) is recorded in the CRF for technical success and procedural success.

    Time frame: From start of procedure surgery until completion of procedure surgery (Percutaneous balloon angioplasty)

  2. Rutherford

    Distribution of Rutherford stages during follow-up as compared to baseline.

    Time frame: Baseline until 12 months after procedure

  3. Mortality

    30-day mortality, 6-months mortality and overall mortality at 12 months.

    Time frame: Until 12 months after procedure

  4. Repeated target lesion revascularization (TLR) rate

    TLR is defined as a repeated procedure (endovascular or surgical) due to a problem arising from the lesion (+1 cm proximally and distally to include edge phenomena) initially treated in surviving patients with preserved limb.

    Time frame: Until 12 months after procedure

  5. Repeated target extremity revascularization (TER) rate

    TER is defined as a procedure (endovascular or surgical) due to a problem arising in the ipsilateral traject (iliac, femoropopliteal and below the knee arteries) remote from the lesion initially treated in surviving patients with preserved limb.

    Time frame: Until 12 months after procedure

  6. Minor and major amputation rate

    Occurrence of minor (below the ankle) and major (above the ankle) amputations.

    Time frame: Until 12 months after procedure

  7. Ankle-Brachial Index (ABI)

    Reporting of Ankle-Brachial Index compared to baseline

    Time frame: Baseline until 12 months after procedure

07

Study locations

9 sites
  • ZNA Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint-Jan
    Brugge, 8000, Belgium
  • ZOL (Ziekenhuis Oost-Limburg)
    Genk, 3600, Belgium
  • Jessa hospital
    Hasselt, 3500, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU Bordeaux
    Bordeau, 33076, France
  • CHU Cermont-Ferrand
    Clermont-Ferrand, France
  • CH Mont-de-Marsan
    Mont-de-Marsan, France
  • Klinikum Arnsberg
    Arnsberg, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Oct 2019, 43 months.

Of 198 interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2016
First posted
Mar 17, 2016
StartActual
Mar 2016
Primary completionActual
Oct 2019
CompletionActual
Nov 2019
Last update
Jan 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02710656
Lead sponsor
Cardionovum GmbH
Collaborators
Archer Research
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
Mar 2016
Primary completion
Oct 2019
Completion
Nov 2019
Last update
Jan 23, 2020

Study contacts

Peter Goverde, Dr.
principal investigator · ZNA Stuivenberg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion